A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis

Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the aggregation of the [beta]-amyloid peptide (A[beta]) is an important factor in AD pathogenesis, we asked...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO reports 2017-09, Vol.18 (9), p.1536
Hauptverfasser: Ye, Lan, Rasmussen, Jay, Kaeser, Stephan A, Marzesco, Anne-Marie, Obermuller, Ulrike, Mahler, Jasmin, Schelle, Juliane, Odenthal, Jörg, Kruger, Christian, Fritschi, Sarah K, Walker, Lary C, Staufenbiel, Matthias, Baumann, Frank, Jucker, Mathias
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page 1536
container_title EMBO reports
container_volume 18
creator Ye, Lan
Rasmussen, Jay
Kaeser, Stephan A
Marzesco, Anne-Marie
Obermuller, Ulrike
Mahler, Jasmin
Schelle, Juliane
Odenthal, Jörg
Kruger, Christian
Fritschi, Sarah K
Walker, Lary C
Staufenbiel, Matthias
Baumann, Frank
Jucker, Mathias
description Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the aggregation of the [beta]-amyloid peptide (A[beta]) is an important factor in AD pathogenesis, we asked whether A[beta] seeds from brain extracts of mice at different stages of amyloid deposition differ in their biological activity. Specifically, we assessed the effect of age on A[beta] seeding activity in two mouse models of cerebral A[beta] amyloidosis (APPPS1 and APP23) with different ages of onset and rates of progression of A[beta] deposition. Brain extracts from these mice were serially diluted and inoculated into host mice. Strikingly, the seeding activity (seeding dose SD50) in extracts from donor mice of both models reached a plateau relatively early in the amyloidogenic process. When normalized to total brain A[beta], the resulting specific seeding activity sharply peaked at the initial phase of A[beta] deposition, which in turn is characterized by a temporary several-fold increase in the A[beta]42/A[beta]40 ratio. At all stages, the specific seeding activity of the APPPS1 extract was higher compared to that of APP23 brain extract, consistent with a more important contribution of A[beta]42 than A[beta]40 to seed activity. Our findings indicate that the A[beta] seeding potency is greatest early in the pathogenic cascade and diminishes as A[beta] increasingly accumulates in brain. The present results provide experimental support for directing anti-A[beta] therapeutics to the earliest stage of the pathogenic cascade, preferably before the onset of amyloid deposition. Synopsis The highest biological seeding activity of A[beta] occurs at the onset of plaque deposition. This points to the need for therapeutic targeting of A[beta] at the very early stages of Alzheimer's disease. The specific seeding activity of A[beta] peaks at the initial phase of A[beta] deposition. The peak in A[beta] seeding activity coincides with a high A[beta]42/A[beta]40 ratio. The overall A[beta] seeding activity of brain extracts plateaus with aging.
doi_str_mv 10.15252/embr.201744067
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1934166843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1934166843</sourcerecordid><originalsourceid>FETCH-proquest_journals_19341668433</originalsourceid><addsrcrecordid>eNqNizsLwjAURoMo-JxdLzhXkzR9jSKKo4ODIFLS9qrV2tTcOPTfK-gPcPoOnPMxNhV8LgIZyAU-MjuXXERK8TDqsIFQYeL5Ioq7P5ZSHPpsSHTjnAdJFA_YbnnM0OkTEGJR1hdojMM6b6FBfScoa3BXBNS2aoGcviCBOUOOFjOrK_iePf1oK1MWhkoas95ZV4ST347YbLPer7ZeY83zheTSm3nZ-qNSkfhKhGGsfP-_6g1EwUXk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1934166843</pqid></control><display><type>article</type><title>A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Ye, Lan ; Rasmussen, Jay ; Kaeser, Stephan A ; Marzesco, Anne-Marie ; Obermuller, Ulrike ; Mahler, Jasmin ; Schelle, Juliane ; Odenthal, Jörg ; Kruger, Christian ; Fritschi, Sarah K ; Walker, Lary C ; Staufenbiel, Matthias ; Baumann, Frank ; Jucker, Mathias</creator><creatorcontrib>Ye, Lan ; Rasmussen, Jay ; Kaeser, Stephan A ; Marzesco, Anne-Marie ; Obermuller, Ulrike ; Mahler, Jasmin ; Schelle, Juliane ; Odenthal, Jörg ; Kruger, Christian ; Fritschi, Sarah K ; Walker, Lary C ; Staufenbiel, Matthias ; Baumann, Frank ; Jucker, Mathias</creatorcontrib><description>Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the aggregation of the [beta]-amyloid peptide (A[beta]) is an important factor in AD pathogenesis, we asked whether A[beta] seeds from brain extracts of mice at different stages of amyloid deposition differ in their biological activity. Specifically, we assessed the effect of age on A[beta] seeding activity in two mouse models of cerebral A[beta] amyloidosis (APPPS1 and APP23) with different ages of onset and rates of progression of A[beta] deposition. Brain extracts from these mice were serially diluted and inoculated into host mice. Strikingly, the seeding activity (seeding dose SD50) in extracts from donor mice of both models reached a plateau relatively early in the amyloidogenic process. When normalized to total brain A[beta], the resulting specific seeding activity sharply peaked at the initial phase of A[beta] deposition, which in turn is characterized by a temporary several-fold increase in the A[beta]42/A[beta]40 ratio. At all stages, the specific seeding activity of the APPPS1 extract was higher compared to that of APP23 brain extract, consistent with a more important contribution of A[beta]42 than A[beta]40 to seed activity. Our findings indicate that the A[beta] seeding potency is greatest early in the pathogenic cascade and diminishes as A[beta] increasingly accumulates in brain. The present results provide experimental support for directing anti-A[beta] therapeutics to the earliest stage of the pathogenic cascade, preferably before the onset of amyloid deposition. Synopsis The highest biological seeding activity of A[beta] occurs at the onset of plaque deposition. This points to the need for therapeutic targeting of A[beta] at the very early stages of Alzheimer's disease. The specific seeding activity of A[beta] peaks at the initial phase of A[beta] deposition. The peak in A[beta] seeding activity coincides with a high A[beta]42/A[beta]40 ratio. The overall A[beta] seeding activity of brain extracts plateaus with aging.</description><identifier>ISSN: 1469-221X</identifier><identifier>EISSN: 1469-3178</identifier><identifier>DOI: 10.15252/embr.201744067</identifier><language>eng</language><publisher>New York: Springer Nature B.V</publisher><subject>Age ; Age factors ; Agglomeration ; Alzheimer's disease ; Amyloidogenesis ; Amyloidosis ; Animal models ; Biological activity ; Biological effects ; Brain ; Deposition ; Dilution ; Neurodegenerative diseases ; Pathogenesis ; Plateaus ; Protein seeding ; Seeding ; Seeds ; Therapeutic targets ; β-Amyloid</subject><ispartof>EMBO reports, 2017-09, Vol.18 (9), p.1536</ispartof><rights>2017 EMBO</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ye, Lan</creatorcontrib><creatorcontrib>Rasmussen, Jay</creatorcontrib><creatorcontrib>Kaeser, Stephan A</creatorcontrib><creatorcontrib>Marzesco, Anne-Marie</creatorcontrib><creatorcontrib>Obermuller, Ulrike</creatorcontrib><creatorcontrib>Mahler, Jasmin</creatorcontrib><creatorcontrib>Schelle, Juliane</creatorcontrib><creatorcontrib>Odenthal, Jörg</creatorcontrib><creatorcontrib>Kruger, Christian</creatorcontrib><creatorcontrib>Fritschi, Sarah K</creatorcontrib><creatorcontrib>Walker, Lary C</creatorcontrib><creatorcontrib>Staufenbiel, Matthias</creatorcontrib><creatorcontrib>Baumann, Frank</creatorcontrib><creatorcontrib>Jucker, Mathias</creatorcontrib><title>A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis</title><title>EMBO reports</title><description>Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the aggregation of the [beta]-amyloid peptide (A[beta]) is an important factor in AD pathogenesis, we asked whether A[beta] seeds from brain extracts of mice at different stages of amyloid deposition differ in their biological activity. Specifically, we assessed the effect of age on A[beta] seeding activity in two mouse models of cerebral A[beta] amyloidosis (APPPS1 and APP23) with different ages of onset and rates of progression of A[beta] deposition. Brain extracts from these mice were serially diluted and inoculated into host mice. Strikingly, the seeding activity (seeding dose SD50) in extracts from donor mice of both models reached a plateau relatively early in the amyloidogenic process. When normalized to total brain A[beta], the resulting specific seeding activity sharply peaked at the initial phase of A[beta] deposition, which in turn is characterized by a temporary several-fold increase in the A[beta]42/A[beta]40 ratio. At all stages, the specific seeding activity of the APPPS1 extract was higher compared to that of APP23 brain extract, consistent with a more important contribution of A[beta]42 than A[beta]40 to seed activity. Our findings indicate that the A[beta] seeding potency is greatest early in the pathogenic cascade and diminishes as A[beta] increasingly accumulates in brain. The present results provide experimental support for directing anti-A[beta] therapeutics to the earliest stage of the pathogenic cascade, preferably before the onset of amyloid deposition. Synopsis The highest biological seeding activity of A[beta] occurs at the onset of plaque deposition. This points to the need for therapeutic targeting of A[beta] at the very early stages of Alzheimer's disease. The specific seeding activity of A[beta] peaks at the initial phase of A[beta] deposition. The peak in A[beta] seeding activity coincides with a high A[beta]42/A[beta]40 ratio. The overall A[beta] seeding activity of brain extracts plateaus with aging.</description><subject>Age</subject><subject>Age factors</subject><subject>Agglomeration</subject><subject>Alzheimer's disease</subject><subject>Amyloidogenesis</subject><subject>Amyloidosis</subject><subject>Animal models</subject><subject>Biological activity</subject><subject>Biological effects</subject><subject>Brain</subject><subject>Deposition</subject><subject>Dilution</subject><subject>Neurodegenerative diseases</subject><subject>Pathogenesis</subject><subject>Plateaus</subject><subject>Protein seeding</subject><subject>Seeding</subject><subject>Seeds</subject><subject>Therapeutic targets</subject><subject>β-Amyloid</subject><issn>1469-221X</issn><issn>1469-3178</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNizsLwjAURoMo-JxdLzhXkzR9jSKKo4ODIFLS9qrV2tTcOPTfK-gPcPoOnPMxNhV8LgIZyAU-MjuXXERK8TDqsIFQYeL5Ioq7P5ZSHPpsSHTjnAdJFA_YbnnM0OkTEGJR1hdojMM6b6FBfScoa3BXBNS2aoGcviCBOUOOFjOrK_iePf1oK1MWhkoas95ZV4ST347YbLPer7ZeY83zheTSm3nZ-qNSkfhKhGGsfP-_6g1EwUXk</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Ye, Lan</creator><creator>Rasmussen, Jay</creator><creator>Kaeser, Stephan A</creator><creator>Marzesco, Anne-Marie</creator><creator>Obermuller, Ulrike</creator><creator>Mahler, Jasmin</creator><creator>Schelle, Juliane</creator><creator>Odenthal, Jörg</creator><creator>Kruger, Christian</creator><creator>Fritschi, Sarah K</creator><creator>Walker, Lary C</creator><creator>Staufenbiel, Matthias</creator><creator>Baumann, Frank</creator><creator>Jucker, Mathias</creator><general>Springer Nature B.V</general><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20170901</creationdate><title>A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis</title><author>Ye, Lan ; Rasmussen, Jay ; Kaeser, Stephan A ; Marzesco, Anne-Marie ; Obermuller, Ulrike ; Mahler, Jasmin ; Schelle, Juliane ; Odenthal, Jörg ; Kruger, Christian ; Fritschi, Sarah K ; Walker, Lary C ; Staufenbiel, Matthias ; Baumann, Frank ; Jucker, Mathias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19341668433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Age factors</topic><topic>Agglomeration</topic><topic>Alzheimer's disease</topic><topic>Amyloidogenesis</topic><topic>Amyloidosis</topic><topic>Animal models</topic><topic>Biological activity</topic><topic>Biological effects</topic><topic>Brain</topic><topic>Deposition</topic><topic>Dilution</topic><topic>Neurodegenerative diseases</topic><topic>Pathogenesis</topic><topic>Plateaus</topic><topic>Protein seeding</topic><topic>Seeding</topic><topic>Seeds</topic><topic>Therapeutic targets</topic><topic>β-Amyloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Lan</creatorcontrib><creatorcontrib>Rasmussen, Jay</creatorcontrib><creatorcontrib>Kaeser, Stephan A</creatorcontrib><creatorcontrib>Marzesco, Anne-Marie</creatorcontrib><creatorcontrib>Obermuller, Ulrike</creatorcontrib><creatorcontrib>Mahler, Jasmin</creatorcontrib><creatorcontrib>Schelle, Juliane</creatorcontrib><creatorcontrib>Odenthal, Jörg</creatorcontrib><creatorcontrib>Kruger, Christian</creatorcontrib><creatorcontrib>Fritschi, Sarah K</creatorcontrib><creatorcontrib>Walker, Lary C</creatorcontrib><creatorcontrib>Staufenbiel, Matthias</creatorcontrib><creatorcontrib>Baumann, Frank</creatorcontrib><creatorcontrib>Jucker, Mathias</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>EMBO reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Lan</au><au>Rasmussen, Jay</au><au>Kaeser, Stephan A</au><au>Marzesco, Anne-Marie</au><au>Obermuller, Ulrike</au><au>Mahler, Jasmin</au><au>Schelle, Juliane</au><au>Odenthal, Jörg</au><au>Kruger, Christian</au><au>Fritschi, Sarah K</au><au>Walker, Lary C</au><au>Staufenbiel, Matthias</au><au>Baumann, Frank</au><au>Jucker, Mathias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis</atitle><jtitle>EMBO reports</jtitle><date>2017-09-01</date><risdate>2017</risdate><volume>18</volume><issue>9</issue><spage>1536</spage><pages>1536-</pages><issn>1469-221X</issn><eissn>1469-3178</eissn><abstract>Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the aggregation of the [beta]-amyloid peptide (A[beta]) is an important factor in AD pathogenesis, we asked whether A[beta] seeds from brain extracts of mice at different stages of amyloid deposition differ in their biological activity. Specifically, we assessed the effect of age on A[beta] seeding activity in two mouse models of cerebral A[beta] amyloidosis (APPPS1 and APP23) with different ages of onset and rates of progression of A[beta] deposition. Brain extracts from these mice were serially diluted and inoculated into host mice. Strikingly, the seeding activity (seeding dose SD50) in extracts from donor mice of both models reached a plateau relatively early in the amyloidogenic process. When normalized to total brain A[beta], the resulting specific seeding activity sharply peaked at the initial phase of A[beta] deposition, which in turn is characterized by a temporary several-fold increase in the A[beta]42/A[beta]40 ratio. At all stages, the specific seeding activity of the APPPS1 extract was higher compared to that of APP23 brain extract, consistent with a more important contribution of A[beta]42 than A[beta]40 to seed activity. Our findings indicate that the A[beta] seeding potency is greatest early in the pathogenic cascade and diminishes as A[beta] increasingly accumulates in brain. The present results provide experimental support for directing anti-A[beta] therapeutics to the earliest stage of the pathogenic cascade, preferably before the onset of amyloid deposition. Synopsis The highest biological seeding activity of A[beta] occurs at the onset of plaque deposition. This points to the need for therapeutic targeting of A[beta] at the very early stages of Alzheimer's disease. The specific seeding activity of A[beta] peaks at the initial phase of A[beta] deposition. The peak in A[beta] seeding activity coincides with a high A[beta]42/A[beta]40 ratio. The overall A[beta] seeding activity of brain extracts plateaus with aging.</abstract><cop>New York</cop><pub>Springer Nature B.V</pub><doi>10.15252/embr.201744067</doi></addata></record>
fulltext fulltext
identifier ISSN: 1469-221X
ispartof EMBO reports, 2017-09, Vol.18 (9), p.1536
issn 1469-221X
1469-3178
language eng
recordid cdi_proquest_journals_1934166843
source Wiley Free Content; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA Free Journals
subjects Age
Age factors
Agglomeration
Alzheimer's disease
Amyloidogenesis
Amyloidosis
Animal models
Biological activity
Biological effects
Brain
Deposition
Dilution
Neurodegenerative diseases
Pathogenesis
Plateaus
Protein seeding
Seeding
Seeds
Therapeutic targets
β-Amyloid
title A[beta] seeding potency peaks in the early stages of cerebral [beta]-amyloidosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A29%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%5Bbeta%5D%20seeding%20potency%20peaks%20in%20the%20early%20stages%20of%20cerebral%20%5Bbeta%5D-amyloidosis&rft.jtitle=EMBO%20reports&rft.au=Ye,%20Lan&rft.date=2017-09-01&rft.volume=18&rft.issue=9&rft.spage=1536&rft.pages=1536-&rft.issn=1469-221X&rft.eissn=1469-3178&rft_id=info:doi/10.15252/embr.201744067&rft_dat=%3Cproquest%3E1934166843%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1934166843&rft_id=info:pmid/&rfr_iscdi=true